The Rise of Philadelphia: A Hub for Cell and Gene Therapy Innovation
Written on
Chapter 1: Introduction to Philadelphia's Biopharma Landscape
Philadelphia has long been celebrated for its rich history, sports culture, and iconic cheesesteaks. However, it is now gaining recognition as a pivotal center for Cell and Gene Therapy. Several factors are aligning to position this city as a premier biopharma hub in the coming years, with industry experts predicting a surge in growth that will further establish its significance in the biopharmaceutical ecosystem.
In October, Philadelphia was ranked seventh among the top ten U.S. biopharma clusters according to Genetic Engineering and Biotechnology News.
As Audrey Greenberg, Executive Managing Director of The Discovery Labs, notes, "A combination of macroeconomic factors is creating unprecedented demand for lab space, manufacturing capacity, and CDMO services, particularly in advanced therapies. The life sciences and biomedical ecosystem in Philadelphia is ideally suited to meet this demand, and The Discovery Labs is expediting market entry with ready-to-use life sciences real estate, manufacturing capacity, and pharmaceutical services."
This burgeoning industry, still in its formative stages, is attracting organizations eager to establish a foothold in the region.
Section 1.1: The Evolution of the Cell and Gene Therapy Industry
To understand why companies are gravitating towards Philadelphia, it's essential to examine the Cell and Gene Therapy industry's evolution and the city's role within it.
Emerging over thirty years ago through the efforts of University of Pennsylvania researchers, the industry faced numerous challenges, including early clinical trial failures and a significant wrongful death lawsuit that stymied progress. However, the introduction of Glybera marked a turning point as it became the first gene therapy to reach commercialization, despite its high cost of $1 million, which ultimately led to its discontinuation.
Continuing their efforts, Penn researchers launched Kymriah in 2017, the first CAR T-cell therapy approved by the FDA, utilizing a patient's own T-cells to combat cancer. Presently, four CAR T-cell therapies have received FDA approval:
- tisagenlecleucel (Kymriah; Novartis)
- axicabtagene ciloleucel (Yescarta; Kite Pharma, Gilead Sciences Inc.)
- lisocabtagene maraleucel (Breyanzi; Juno Therapeutics)
- brexucabtagene autoleucel (Tecartus; Kite Pharma, Gilead Sciences Inc.)
The landscape is promising, with many innovative therapies in various clinical development stages, driven by a clearer path to commercialization and supported by skilled professionals.
Join Us at Cellicon Valley '23: The Future of Cell and Gene Therapies - YouTube
The video highlights the advancements and potential of cell and gene therapies, particularly in Philadelphia.
Section 1.2: Key Factors Driving Growth
Philadelphia is uniquely positioned to lead the charge in this technological evolution due to several compelling factors:
- Cost of Living: While cities like Boston and San Francisco dominate the current landscape, their high living costs create barriers for many professionals. Philadelphia offers more affordable real estate and business costs, making it an attractive alternative.
- Talent Pool: The greater Philadelphia area boasts a rich array of academic institutions and life sciences companies, providing a robust talent pipeline. With over 70,000 life sciences professionals, including 10,000 specializing in cell and gene therapy, the region is well-equipped to support industry growth.
- Corporate Clusters: With more than 30 cell and gene therapy companies and 60 labs, alongside the presence of major pharmaceutical firms such as GlaxoSmithKline and Johnson & Johnson, Philadelphia is becoming a hotbed for innovation.
- Innovation: Home to renowned institutions like the University of Pennsylvania and the Children's Hospital of Philadelphia, the city is a hub for groundbreaking research and development in cell and gene therapies.
- Capital Investment: Philadelphia is attracting significant private investment, evidenced by a record number of IPOs in the life sciences sector in 2020, alongside ongoing support from local institutions.
- Strategic Location: Proximity to an international airport with cold chain storage capabilities is crucial for advanced therapeutics. Local initiatives are underway to enhance Philadelphia's status as a center for cell and gene therapy.
- Tax Incentives: Companies setting up in Keystone Opportunity Areas may benefit from substantial tax savings, ranging from $10 to $20 per square foot annually, fostering a favorable business environment.
Chapter 2: Challenges and Future Outlook
Despite its advantages, the cell and gene therapy sector faces challenges, primarily related to access to manufacturing capacity and skilled talent. As demand for manufacturing capabilities grows, Philadelphia must continue to develop its infrastructure and workforce to remain competitive.
The next few years are poised for significant advancements in therapy development, with Philadelphia playing a vital role in shaping the future of the cell and gene industry.
Sources: